Form 4: Tivic Health Director Granted Future Stock Options

Tivic Health Systems Director Christina Rizopoulos Valauri was granted 7,500 stock options with a $3.32 exercise price, vesting over one year from August 6, 2025.

Summary

• Christina Rizopoulos Valauri, a Director of Tivic Health Systems, Inc. (TIVC), was granted 7,500 stock options.
• The stock options have an exercise price of $3.32 per share.
• The grant date for these options is August 6, 2025.
• The options will vest in four successive equal quarterly installments, with 100% vesting upon the first anniversary of the grant date.
• The expiration date for these options is August 5, 2035.
• Following this transaction, Christina Rizopoulos Valauri beneficially owns 7,500 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for aligning interests and incentivizing long-term performance, indicating confidence in future growth, though it's a standard compensation event rather than a major strategic announcement.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration period, providing a long window for potential value realization contingent on stock price appreciation.

Negatives

• The value of the options is entirely contingent on the future stock price exceeding the $3.32 exercise price.
• There is no immediate cash benefit to the director from this grant.

Risks

• The value of the stock options is contingent on the future performance of Tivic Health Systems, Inc.'s common stock.
• If the stock price does not exceed the exercise price of $3.32, the options may expire worthless.

Future Outlook

The granting of long-term stock options suggests a management expectation of future stock price appreciation and long-term value creation for Tivic Health Systems, Inc.

Industry Context

Granting stock options to directors is a common practice across various industries, including healthcare technology, to align executive incentives with shareholder interests and aid in talent retention.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including healthcare technology.
• The vesting schedule of one year (four quarterly installments) is a common approach to ensure continued commitment from the director.
• The 10-year expiration period for stock options is also typical for such grants, providing ample time for the options to become in-the-money.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of director incentives with long-term stock performance.

Next Steps

• The stock options will vest in four equal quarterly installments over the next year, starting from August 6, 2025.

Key Dates

Recommendation

The filing details a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning interests. This event alone does not provide sufficient new information to alter an investment thesis, thus a 'hold' recommendation is appropriate for existing positions.

Keywords

Tivic Health Systems, TIVC, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership